si-TAL-oh-pram 
Unlabeled Use:
Contraindicated in:
Use Cautiously in:
CV: QT interval prolongation, postural hypotension, tachycardia, TORSADES DE POINTES.
Derm: sweating, photosensitivity, pruritus, rash.
EENT: abnormal accommodation.
Endo: SIADH.
F and E: hyponatremia.
GI: ↑ salivation, abdominal pain, anorexia, diarrhea, dry mouth, dyspepsia, flatulence, nausea, altered taste, vomiting.
GU: ↓ libido, amenorrhea, delayed/absent orgasm, dysmenorrhea, ejaculatory delay/failure, erectile dysfunction, polyuria.
Hemat: BLEEDING.
Metab: ↑ appetite, weight gain, weight loss.
MS: arthralgia, myalgia.
Neuro: apathy, confusion, drowsiness, insomnia, tremor, weakness, ↓ libido, ↑ depression, agitation, amnesia, anxiety, dizziness, fatigue, impaired concentration, migraine headache, NEUROLEPTIC MALIGNANT SYNDROME, paresthesia, SUICIDAL THOUGHTS.
Resp: cough.
Misc: fever, SEROTONIN SYNDROME, yawning.
Drug-Drug:
Drug-Natural Products:
(Generic available)
Hepatic Impairment
Therapeutic Classification: antidepressants
Pharmacologic Classification: selective serotonin reuptake inhibitors ssris
Absorption: 80% absorbed after oral administration.
Distribution: Enters breast milk.
Metabolism/Excretion: Mostly metabolized by the liver (10% by the CYP3A4 and CYP2C19 isoenzymes); the CYP2C19 isoenzyme exhibits genetic polymorphism (2% of Whites, 4% of Blacks, and 14% of Asians may be poor metabolizers and may have significantly ↑ citalopram concentrations and an ↑ risk of adverse effects). Excreted unchanged in the urine.
Half-life: 35 hr.
NDC Code*
